Transcription of STABILITY TESTING OF ACTIVE PHARMACEUTICAL …
{{id}} {{{paragraph}}}
Working document January 2017. Draft document for comment 1 STABILITY TESTING OF ACTIVE . 2 PHARMACEUTICAL ingredients AND. 3 finished PHARMACEUTICAL PRODUCTS. 4 (January 2017). 5 DRAFT FOR COMMENT. Should you have any comments on the attached text and the STABILITY conditions for WHO Member States (MS) by Region, appendixed to the previous version of this guidance ( ), please send these to: Dr Sabine Kopp, Group Lead, Medicines Quality Assurance, Technologies Standards and Norms, World Health Organization, 1211 Geneva 27, Switzerland; email: fax: (+41 22) 791 4730.
Working document QAS/17.694 January 2017 Draft document for comment 1 STABILITY TESTING OF ACTIVE 2 PHARMACEUTICAL INGREDIENTS AND 3 FINISHED PHARMACEUTICAL PRODUCTS ...
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}
Guideline on stability testing for applications for, A Stability Testing Guidelines:, STABILITY TESTING, GUIDELINE, Q1A(R2) Guideline Stability Testing of New, Stability testing of active pharmaceutical, Stability, On Stability Testing, STABILITY TESTING OF ACTIVE SUBSTANCES, Stability testing of active substances and pharmaceutical products, Long Term Stability Testing Conditions:, Long Term Stability Testing Conditions: Position, Guideline stability testing, STABILITY TESTING Photostability